CoChat
Sign Up
Cited by 27

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Genetic study evaluating LDLR polymorphisms and Alzheimer's disease

Lämsä, R., Helisalmi, S., Herukka, S.-K., Tapiola, T., Pirttilä, T., Vepsäläinen, S., Hiltunen, M., Soininen, H.·2008·Neurobiology of Aging
DOI 10.1016/j.neurobiolaging.2006.12.009
Open this paper in CoChat — free account

Abstract

We genotyped SNPs rs11668477, rs12983082, rs11669576, rs2738444, rs5925 and rs1433099 in 405 Finnish AD cases and 463 controls and conducted a single allele and genotypic distribution comparison and estimated the haplotype frequencies between cases and controls and evaluated the level of biomarkers in haplotype carriers. We observed that T allele of rs2738444 was overrepresented in AD women with p=0.014 (Bonferroni corrected p=0.252). A specific haplotype block consisting of SNPs rs11669576, rs2738444 and rs5925 was identified and in women the haplotype GTT was overrepresented in AD cases when compared to controls with p=0.008. We measured CSF Abeta(42), tau and phosphorylated tau (ptau) levels in a subgroup of cases and controls and found that some genotypes were associated with increased levels of tau and ptau or a decreased Abeta(42) level in women. The specific risk haplotype GTT was associated with an increased level of tau and ptau in both men and women. Our findings suggest that LDLR gene may be associated with AD risk and its CSF biomarkers, especially in women.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.neurobiolaging.2006.12.009

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Several groups identified a potential contribution of LDLR to AD and investigated potential links, with some apparently opposing results.

    “Several groups identified a potential contribution of LDLR to AD and investigated potential links, for example by crossing AD transgenic mice with the LDLR−/− mouse model of hypercholesterolemia to investigate the effects of LDLR deficiency [30]–[40]. Some apparently opposing results were obtained.”

    From LDLR Expression and Localization Are Altered in Mouse and Human Cell Culture Models of Alzheimer's Disease (2010) · cites this paper as [32]

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 28

  1. Ahn, 1994, Role of common genetic polymorphisms in the LDL receptor gene in affecting plasma cholesterol levels in the general population, Arterioscler. Thromb., 14, 663, 10.1161/01.ATV.14.5.663 · DOI
  2. Cheng, 2005, Functional interaction between APOE4 and LDL receptor isoforms in Alzheimer's disease, J. Med. Genet., 42, 129, 10.1136/jmg.2004.024968 · DOI · Paper page
  3. Gopalraj, 2005, Genetic association of low density lipoprotein receptor and Alzheimer's disease, Neurobiol. Aging, 26, 1, 10.1016/j.neurobiolaging.2004.09.001 · DOI · Paper page
  4. Gudnason, 1995, Effect of the StuI polymorphism in the LDL receptor gene (ala 370 to thr) on lipid levels in healthy individuals, Clin. Genet., 47, 68, 10.1111/j.1399-0004.1995.tb03926.x · DOI
  5. Hampel, 2004, Core biological marker candidates of Alzheimer's disease-perspectives for diagnosis, prediction of outcome and reflection of biological activity, J. Neural. Transm., 111, 247, 10.1007/s00702-003-0065-z · DOI
  6. Hardy, 1997, Amyloid, the presenilins and Alzheimer's disease, Trends Neurosci., 20, 154, 10.1016/S0166-2236(96)01030-2 · DOI · Paper page
  7. Herukka, 2005, CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment, Neurology, 64, 1294, 10.1212/01.WNL.0000156914.16988.56 · DOI
  8. Herukka, S.K., Helisalmi, S., Hallikainen, M., Tervo, S., Soininen, H., Pirttila, T., 2006. CSF Abeta42, tau and phosphorylated tau, APOE varepsilon4 allele and MCI type in progressive MCI. Neurobiol. Aging, published online ahead of print. · DOI
  9. Hulstaert, 1999, Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF, Neurology, 52, 1555, 10.1212/WNL.52.8.1555 · DOI · Paper page
  10. Kalvodova, 2005, Lipids as modulators of proteolytic activity of BACE: Involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro, J. Biol. Chem., 280, 36815, 10.1074/jbc.M504484200 · DOI
  11. Kivipelto, 2002, Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease, Ann. Intern. Med., 137, 149, 10.7326/0003-4819-137-3-200208060-00006 · DOI
  12. Lehtovirta, 1996, Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: relation to apolipoprotein E polymorphism, Neurology, 46, 413, 10.1212/WNL.46.2.413 · DOI
  13. Lendon, 1997, Genetic association studies between dementia of the Alzheimer's type and three receptors for apolipoprotein E in a Caucasian population, Neurosci. Lett., 222, 187, 10.1016/S0304-3940(97)13381-X · DOI
  14. Levy-Lahad, 1995, Candidate gene for the chromosome 1 familial Alzheimer's disease locus, Science, 269, 973, 10.1126/science.7638622 · DOI · Paper page
  15. McKhann, 1984, Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease, Neurology, 34, 939, 10.1212/WNL.34.7.939 · DOI · Paper page
  16. Mollenhauer, 2005, Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer's disease, J. Neural. Transm., 112, 933, 10.1007/s00702-004-0235-7 · DOI
  17. Raber, 2004, Androgens, apoE, and Alzheimer's disease, Sci. Aging Knowl. Environ., 11
  18. Rahman, 2005, High cholesterol diet induces tau hyperphosphorylation in apolipoprotein E deficient mice, FEBS Lett., 579, 6411, 10.1016/j.febslet.2005.10.024 · DOI
  19. Refolo, 2000, Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model, Neurobiol. Dis., 7, 321, 10.1006/nbdi.2000.0304 · DOI · Paper page
  20. Rodriguez, E., Mateo, I., Llorca, J., Sanchez-Quintana, C., Infante, J., Berciano, J., Combarros, O., 2005. Genetic interaction between two apolipoprotein E receptors increases Alzheimer's disease risk. J. Neurol., Published online ahead of print. · DOI
  21. Saunders, 1993, Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease, Neurology, 43, 1467, 10.1212/WNL.43.8.1467 · DOI · Paper page
  22. Sherrington, 1995, Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease, Nature, 375, 754, 10.1038/375754a0 · DOI · Paper page
  23. Sjogren, 2001, Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: Establishment of reference values, Clin. Chem., 47, 1776, 10.1093/clinchem/47.10.1776 · DOI · Paper page
  24. Sunderland, 2004, Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele, Biol. Psychiatry, 56, 670, 10.1016/j.biopsych.2004.07.021 · DOI · Paper page
  25. Tregouet, 2004, A new algorithm for haplotype-based association analysis: the stochastic-EM algorithm, Ann. Hum. Genet., 68, 165, 10.1046/j.1529-8817.2003.00085.x · DOI
  26. Vuorio, 2001, Familial hypercholesterolaemia in Finland: common, rare and mild mutations of the LDL receptor and their clinical consequences. Finnish FH-group, Ann. Med., 33, 410, 10.3109/07853890108995954 · DOI
  27. Wijsman, 2004, Evidence for a novel late-onset Alzheimer disease locus on chromosome 19p13.2, Am. J. Hum. Genet., 75, 398, 10.1086/423393 · DOI · Paper page
  28. Yao, 2002, Function of beta-amyloid in cholesterol transport: a lead to neurotoxicity, FASEB J., 16, 1677, 10.1096/fj.02-0285fje · DOI

Cited by

Sorted by citations

Metadata

Authors
Lämsä, R., Helisalmi, S., Herukka, S.-K., Tapiola, T., Pirttilä, T., Vepsäläinen, S., Hiltunen, M., & Soininen, H.
Venue
Neurobiology of Aging
Publisher
Elsevier BV
Published
2008-06
Volume
29
Issue
6
Pages
848-855
ISSN
0197-4580
DOI
10.1016/j.neurobiolaging.2006.12.009
Cited by
27
References
1
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review